Literature DB >> 25017682

Antiviral drug allergy.

Brigitte Milpied-Homsi1, Ellen M Moran2, Elizabeth J Phillips3.   

Abstract

Antiviral drugs used to treat HIV and hepatitis C are common causes of delayed drug hypersensitivities for which many of the more severe reactions have been recently shown to be immunogenetically mediated such as abacavir hypersensitivity where HLA-B(∗)57:01 is now used routinely as a screening test to exclude patients carrying this allele from abacavir prescription. Most antiviral drug allergies consist of mild to moderate delayed rash without other serious features (eg, fever, mucosal involvement, blistering rash, organ impairment. In these cases treatment can be continued with careful observation and symptomatic management and the discontinuation rate is low.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Abacavir; Altered peptide repertoire; Antiretroviral; Human leukocyte antigen; Major histocompatibility complex; Nevirapine; Telaprevir pharmacogenomics

Mesh:

Substances:

Year:  2014        PMID: 25017682      PMCID: PMC4140860          DOI: 10.1016/j.iac.2014.04.011

Source DB:  PubMed          Journal:  Immunol Allergy Clin North Am        ISSN: 0889-8561            Impact factor:   3.479


  75 in total

1.  The first case of efavirenz-induced photosensitivity in a Japanese patient with HIV infection.

Authors:  Eiichiro Yoshimoto; Mitsuru Konishi; Ken Takahashi; Koichi Murakawa; Koichi Maeda; Keiichi Mikasa; Yukio Yamashina
Journal:  Intern Med       Date:  2004-07       Impact factor: 1.271

2.  Raltegravir-induced DRESS syndrome.

Authors:  Pierre Loulergue; Olivier Mir
Journal:  Scand J Infect Dis       Date:  2012-07-17

Review 3.  Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy.

Authors:  Rebecca Pavlos; Simon Mallal; David Ostrov; Yuri Pompeu; Elizabeth Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2014 Jan-Feb

4.  First case of drug rash eosinophilia and systemic symptoms due to boceprevir.

Authors:  Agnès Samain; Anne-Bénédicte Duval-Modeste; Pascal Joly; Céline Leblanc; Nathalie Massy; Philippe Courville; Odile Goria; Ghassan Riachi
Journal:  J Hepatol       Date:  2013-12-12       Impact factor: 25.083

5.  High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a prospective cohort study.

Authors:  G Yimer; W Amogne; A Habtewold; E Makonnen; N Ueda; A Suda; A Worku; W E Haefeli; J Burhenne; G Aderaye; L Lindquist; E Aklillu
Journal:  Pharmacogenomics J       Date:  2011-08-23       Impact factor: 3.550

6.  Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.

Authors:  J P Fagot; M Mockenhaupt; J N Bouwes-Bavinck; L Naldi; C Viboud; J C Roujeau
Journal:  AIDS       Date:  2001-09-28       Impact factor: 4.177

7.  Genetic variations in HLA-B region and hypersensitivity reactions to abacavir.

Authors:  Seth Hetherington; Arlene R Hughes; Michael Mosteller; Denise Shortino; Katherine L Baker; William Spreen; Eric Lai; Kirstie Davies; Abigail Handley; David J Dow; Mary E Fling; Michael Stocum; Clive Bowman; Linda M Thurmond; Allen D Roses
Journal:  Lancet       Date:  2002-03-30       Impact factor: 79.321

8.  Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity.

Authors:  Diana Chessman; Lyudmila Kostenko; Tessa Lethborg; Anthony W Purcell; Nicholas A Williamson; Zhenjun Chen; Lars Kjer-Nielsen; Nicole A Mifsud; Brian D Tait; Rhonda Holdsworth; Coral Ann Almeida; David Nolan; Whitney A Macdonald; Julia K Archbold; Anthony D Kellerher; Debbie Marriott; Simon Mallal; Mandvi Bharadwaj; Jamie Rossjohn; James McCluskey
Journal:  Immunity       Date:  2008-06       Impact factor: 31.745

9.  Dermatological side-effects of telaprevir-based triple therapy for chronic hepatitis C in phase III trials in Japan.

Authors:  Hideshi Torii; Hirohiko Sueki; Hiromitsu Kumada; Yuko Sakurai; Keiji Aoki; Ichimaro Yamada; Mamitaro Ohtsuki
Journal:  J Dermatol       Date:  2013-06-05       Impact factor: 4.005

10.  Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population.

Authors:  Daniel F Carr; Mas Chaponda; Andrea L Jorgensen; Elena Cornejo Castro; Joep J van Oosterhout; Saye H Khoo; David G Lalloo; Robert S Heyderman; Ana Alfirevic; Munir Pirmohamed
Journal:  Clin Infect Dis       Date:  2013-01-29       Impact factor: 9.079

View more
  4 in total

1.  Report from the National Institute of Allergy and Infectious Diseases workshop on drug allergy.

Authors:  Lisa M Wheatley; Marshall Plaut; Julie M Schwaninger; Aleena Banerji; Mariana Castells; Fred D Finkelman; Gerald J Gleich; Emma Guttman-Yassky; Simon A K Mallal; Dean J Naisbitt; David A Ostrov; Elizabeth J Phillips; Werner J Pichler; Thomas A E Platts-Mills; Jean-Claude Roujeau; Lawrence B Schwartz; Lauren A Trepanier
Journal:  J Allergy Clin Immunol       Date:  2015-08       Impact factor: 10.793

2.  Nevirapine induced mitochondrial dysfunction in HepG2 cells.

Authors:  Atchara Paemanee; Wannapa Sornjai; Suthathip Kittisenachai; Naraporn Sirinonthanawech; Sittiruk Roytrakul; Jeerang Wongtrakul; Duncan R Smith
Journal:  Sci Rep       Date:  2017-08-23       Impact factor: 4.379

Review 3.  Antimicrobial Desensitization: A Review of Published Protocols.

Authors:  Daniel B Chastain; Vanessa Johanna Hutzley; Jay Parekh; Jason Val G Alegro
Journal:  Pharmacy (Basel)       Date:  2019-08-09

Review 4.  Medicinal Fungi with Antiviral Effect.

Authors:  Yu Zhang; Guoying Zhang; Jianya Ling
Journal:  Molecules       Date:  2022-07-12       Impact factor: 4.927

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.